It’s now well established that obesity, visceral (belly) fat and type 2 diabetes (i.e., metabolic dysfunction) increase a person’s risk for developing certain cancers. What is only beginning to be appreciated is that cancer patients that have underlying metabolic dysfunction have much worse outcomes and seriously increased mortality rates. This suggests that metabolic hormones play an important role in cancer progression, and could be valuable targets in cancer treatment.